Nathaniel David
{{short description|American scientist and entrepreneur|bot=PearBOT 5}}
{{Infobox scientist
| name = Nathaniel David
| image = Nathaniel David 2.jpg
| image_size =
| birth_place = San Francisco, California, U.S.
| nationality = American
| alma_mater = Harvard University, University of California, Berkeley
| known_for = Kythera Biopharmaceuticals, Kybella, Jupiter Bioventures
| awards = MIT Technology Review Young Innovators Under 35
| field = Biotechnology
| work_institution = Kythera Biopharmaceuticals, Unity Biotechnology, Jupiter Bioventures
}}
Nathaniel David is an American scientist and biotechnology entrepreneur who has co-founded several life sciences companies that together have raised more than $1.5 billion in financing and contributed to the development of multiple FDA-approved medicines, including alogliptin, trelagliptin, Zemiglo (Zemdi), [https://zemdri.com Zemdri], and [https://www.mykybella.com/ Kybella].
Biography
= Education and Career =
David earned an A.B. in Biology from Harvard University and a Ph.D. in Molecular and Cellular Biology from University of California, Berkeley.{{Cite web |date=22 February 2004 |title=Biotech on brink of breakthroughs |url=http://www.sfgate.com/business/article/Biotech-on-brink-of-breakthroughs-2792671.php |access-date=2016-03-09 |website=SFGate}} While completing his doctorate, he co-founded Syrrx in 1999. The company developed a high-throughput structural biology platform that used automation and miniaturization to accelerate protein structure determination.{{Cite news|url=https://www.nytimes.com/2000/07/04/science/analyzing-proteins-with-x-rays-crystals-and-some-luck.html|title=Analyzing Proteins With X-Rays, Crystals and Some Luck|last=Pollack|first=Andrew|date=2000-07-04|newspaper=The New York Times|issn=0362-4331|access-date=2016-03-09}}{{Cite news|url=https://www.nytimes.com/2000/07/04/science/the-next-chapter-in-the-book-of-life-is-written-in-the-proteins.html|title=The Next Chapter in the Book of Life Is Written in the Proteins|last=Pollack|first=Andrew|date=2000-07-04|newspaper=The New York Times|issn=0362-4331|access-date=2016-03-09}} David was named to the MIT Technology Review TR35, a list of top global innovators under the age of 35. Syrrx was acquired by Takeda Pharmaceutical Company in 2005, and its research contributed to the development of Nesina (alogliptin), a diabetes drug approved by the FDA.{{Cite news|url=https://www.nytimes.com/2005/04/20/theater/some-in-biotech-prefer-an-acquisition-to-an-ipo.html|title=Some in Biotech Prefer an Acquisition to an I.P.O.|last=Pollack|first=Andrew|date=2005-04-20|newspaper=The New York Times|issn=0362-4331|access-date=2016-03-09}}{{Cite journal|last1=Parsa|first1=Kishore Vl|last2=Pal|first2=Manojit|date=2011-08-01|title=Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview|journal=Expert Opinion on Drug Discovery|volume=6|issue=8|pages=855–869|doi=10.1517/17460441.2011.588695|issn=1746-045X|pmid=22651127|s2cid=24271265}}
David later co-founded Achaogen (NASDAQ: AKAO), focused on developing treatments for antibiotic-resistant infections. Achaogen developed [https://zemdri.com Zemdri] (plazomicin), which was approved by the FDA for complicated urinary tract infections.
In 2005, David co-founded Kythera Biopharmaceticals (NASDAQ: KYTH), where he served as Chief Science Officer. The company developed [https://www.mykybella.com/ Kybella], the first FDA-approved injectable drug for reducing submental fat.{{Cite press release|date=April 29, 2015|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm444978.htm|title=FDA approves treatment for fat below the chin|publisher=U.S. Food and Drug Administration|language=en|access-date=2016-03-09|url-status=dead|archive-url=https://web.archive.org/web/20150501175027/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm444978.htm|archive-date=2015-05-01}} Kythera went public in 2012 and was acquired by Allergan in 2015 for $2.1 billion.{{Cite web|url=https://www.bloomberg.com/news/articles/2015-06-17/allergan-to-buy-kythera-biopharmaceuticals-for-2-1-billion|title=Allergan to Buy Kythera Biopharmaceuticals for $2.1 Billion|last=Sachetta|first=Ryan|website=Bloomberg.com|access-date=2016-03-09}}{{Cite web|url=http://www.fiercebiotech.com/special-reports/top-10-biotech-ipos-2012|title=Top 10 biotech IPOs of 2012|website=FierceBiotech|access-date=2016-03-09}}
In 2011, he also co-founded [https://unitybiotechnology.com/ UNITY Biotechnology] (NASDAQ: UBX).{{Cite web|url=http://www.fiercebiotech.com/story/backed-lineup-marquee-vcs-biotech-startup-tackles-hard-science-aging/2016-02-03|title=Backed by a lineup of marquee VCs, Unity Biotechnology tackles the hard science of aging|website=FierceBiotech|access-date=2016-03-09}}{{cite web|url=https://www.sec.gov/Archives/edgar/data/1463361/000119312518108850/d535851ds1.htm |title=Unity SEC S-1 Form|date=April 5, 2018|via=sec.gov|access-date=2018-11-14}}{{Cite web|url=http://fortune.com/2016/02/03/mayo-unity-biotechnology-anti-aging/|title=Mayo Clinic Taps Silicon Valley to Help People Age Gracefully|website=Fortune|access-date=2016-03-09}}{{Cite web|url=https://www.theatlantic.com/science/archive/2016/02/clearing-retired-cells-extends-life/459723/|title=Clearing the Body's Retired Cells Slows Aging and Extends Life|last=Yong|first=Ed|website=The Atlantic|date=3 February 2016|language=en-US|access-date=2016-03-09}}{{Cite web|url=https://www.npr.org/sections/health-shots/2016/02/03/465354874/boosting-lifespan-by-clearing-out-cellular-clutter|title=Boosting Life Span By Clearing Out Cellular Clutter|website=NPR.org|access-date=2016-03-09}}
= Recent Work =
In 2021, David co-founded [https://www.jupiter.bio/ Jupiter Bioventures] with former National Cancer Institute director Ned Sharpless. Jupiter Bioventures is a venture foundry that supports the development of therapeutic companies based on emerging biological science. It launched with an initial fund of $70 million and focuses on areas such as oncology and immunology.
References
{{reflist}}
{{authority control}}
{{DEFAULTSORT:David, Nathaniel}}
Category:American molecular biologists
Category:Harvard College alumni